Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 2Sarcoma 1Lymphoid 1Genitourinary 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Osteosarcoma 7Wilms Tumor 6Sarcoma 6Rhabdomyosarcoma 6Rhabdoid Tumor 6Neuroblastoma 6Lymphoma, Non-Hodgkin 6Hepatoblastoma 6Neuroectodermal Tumors, Primitive, Peripheral 5Medulloblastoma 5Histiocytosis, Langerhans-Cell 5Glioma 5Ependymoma 5Sarcoma, Ewing 4Central Nervous System Neoplasms 4Desmoid Tumors 2Xanthogranuloma, Juvenile 1Sarcoma, Synovial 1Rhabdomyosarcoma, Embryonal 1Rhabdomyosarcoma, Alveolar 1Ovarian Neoplasms 1Melanoma 1Lymphoma 1Liposarcoma, Myxoid 1Histiocytic Sarcoma 1Endometrial Neoplasms 1Colorectal Neoplasms 1Chordoma 1Carcinosarcoma 1Carcinoma, Hepatocellular 1

Interventions

Filgrastim 14Cyclophosphamide 13Carboplatin 12Paclitaxel 8Ifosfamide 8Doxorubicin 8pembrolizumab 7Peripheral Blood Stem Cell Transplantation 6Gemcitabine 6fludarabine 5Temozolomide 5Specimen Handling 5Radiotherapy 5Cisplatin 5Magnetic Resonance Spectroscopy 4Etoposide 4Docetaxel 4Amifostine 4aldesleukin 3Trastuzumab 3Taxes 3Psychiatric Rehabilitation 3Melphalan 3Fulvestrant 3Bevacizumab 3sodium thiosulfate 2pazopanib 2pamiparib 2palbociclib 2etoposide phosphate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ovarian Neoplasms × Phantoms, Imaging × Sarcoma × Clear all
NCT04851119 2026-05-05

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Children's Oncology Group

Phase 1/2 Recruiting
147 enrolled
CNSDermatologicGastrointestinalGenitourinaryGynecologicLymphoidSarcoma

Carcinoma, Hepatocellular, Lymphoma, Non-Hodgkin, Melanoma, Wilms Tumor, Neuroblastoma, Ovarian Neoplasms, Sarcoma, Ewing, Osteosarcoma, Colorectal Neoplasms, Endometrial Neoplasms, Hepatoblastoma, Desmoid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡